Pieris Pharmaceuticals Inc. (PIRS)
$13.26
$-2.87
(-17.79%)
As on 13-Dec-2024 16:03EDT
Market cap
$21 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
1.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
1,320,240
10 Years Aggregate
CFO
$-203.25 Mln
EBITDA
$-243.17 Mln
Net Profit
$-251.26 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pieris Pharmaceuticals (PIRS)
| 7,185.7 | -17.7 | -22.1 | 8,345.9 | 61.1 | 30.8 | -- |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Pieris Pharmaceuticals (PIRS)
| -82.5 | -72.5 | 51.2 | -30.9 | 36.1 | -64.6 | 437.3 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pieris Pharmaceuticals (PIRS)
|
13.3 | 21.1 | 1.4 | -16.0 | -1,156.1 | -83.5 | -- | 1.1 |
| 60.0 | 2,342.0 | 0.0 | -76.3 | -1,093,125.0 | -25.9 | -- | 8.5 | |
| 4.3 | 37.5 | 2.2 | -34.9 | -1,302.3 | -312.4 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Pieris Pharmaceuticals (PIRS)
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO... bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts. Read more
-
CEO, President & Director
Mr. Stephen S. Yoder J.D.
-
CEO, President & Director
Mr. Stephen S. Yoder J.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pieris Pharmaceuticals (PIRS)
What is the current share price of Pieris Pharmaceuticals Inc (PIRS) Today?
The share price of Pieris Pharmaceuticals Inc (PIRS) is $13.26 (NASDAQ) as of 13-Dec-2024 16:03 EDT. Pieris Pharmaceuticals Inc (PIRS) has given a return of 61.12% in the last 3 years.
What is the current PB & PE ratio of Pieris Pharmaceuticals Inc (PIRS)?
Since, TTM earnings of Pieris Pharmaceuticals Inc (PIRS) is negative, P/E ratio is not available.
The P/B ratio of Pieris Pharmaceuticals Inc (PIRS) is 1.10 times as on 13-Dec-2024, a 79 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Pieris Pharmaceuticals Inc (PIRS)?
The 52-week high and low of Pieris Pharmaceuticals Inc (PIRS) are Rs -- and Rs -- as of 02-Sep-2026.
What is the market cap of Pieris Pharmaceuticals Inc (PIRS)?
Pieris Pharmaceuticals Inc (PIRS) has a market capitalisation of $ 21 Mln as on 13-Dec-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Pieris Pharmaceuticals Inc (PIRS)?
Before investing in Pieris Pharmaceuticals Inc (PIRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.